What's in Cogent Biosciences, Inc.'s pipeline?

Cogent Biosciences, Inc. has 5 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 3 in Phase 1.

Which companies overlap with Cogent Biosciences, Inc.'s portfolio?

Top competitors by shared drug class: Beijing InnoCare Pharma Tech Co., Ltd., Technische Universität Dresden.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/cogent-biosciences-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Cogent Biosciences, Inc. — Portfolio Competitive Intelligence Brief

Cogent Biosciences, Inc. pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
CGT9486 plus sunitinib	CGT9486 plus sunitinib	phase 3	FLT3 inhibitor; multi-targeted tyrosine kinase inhibitor	FLT3; PDGFR; KIT; VEGFR	Oncology
CGT9486	CGT9486	phase 3	FLT3 inhibitor	FLT3	Oncology

Therapeutic area mix

Oncology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Beijing InnoCare Pharma Tech Co., Ltd. · 1 shared drug class
Technische Universität Dresden · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Cogent Biosciences, Inc.:

Cite this brief

Drug Landscape (2026). Cogent Biosciences, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cogent-biosciences-inc. Accessed 2026-05-16.